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Purpose: Endothelial-derived vasordaxants such as prostacyclin and nitric oxide (NO) 
induce vascular smooth muscle relaxation through activation of cyclic nucleotide-depen- 
dent cellular signaling pathways. However, the specific events that lead to dissociation of 
actin and myosin and relaxation are not known. The purpose of this investigation was to 
determine the late phase signaling events that modulate vascular smooth muscle relax- 
ation. 
Methods: Fresh bovine carotid artery smooth muscle (BCASM) contractile responses were 
determined in a muscle bath under Ca2+-containing and Ca2+-free conditions. Physio- 
logic responses were correlated with phosphorylation events using whole cell phosphor- 
ylation and two-dimensional gel electrophoresis. 
Results: Cyclic nucleotide-dependent vasorelaxation can occur without detectable changes 
in intracellular Ca 2+ concentrations. However, vascular smooth muscles that had been 
precontracted with the phosphatase inhibitor calyculin were refractory to relaxation. 
Vascular smooth muscle relaxation was associated with an increase in the phosphoryla- 
don of two 20 kDa proteins under Ca2+-containing and Ca2+-free conditions. 
Conclusions: These results uggest that Ca 2+-independent mechanisms may also modulate 
vascular smooth muscle relaxation. Two possible late phase signaling mechanisms include 
phosphatase activation and an increase in the phosphorylation of two 20 kDa 
phosphoproteins. (J Vase Surg 1997;25:390-7.) 
Endothelial-derived vasorelaxants such as prosta- 
cyclin and nitric oxide (NO) induce vascular smooth 
muscle relaxation. Endothelial injury that results in 
the loss of production of these paracrine mediators 
has been implicated in alterations in vasomotor tone, 
vasospasm, and atherogenesis. Treatment of vascular 
smooth muscles with NO or NO donors such as 
sodium nitroprusside (SNP) activate guanylate W- 
clase, resulting in increases in cyclic guanosine 
monophosphate (cGMP) and activation of cGMP- 
dependent protein kinase (PKG, Fig. 1). 1 Isoproter- 
enol, prostacyclin, and forskolin (FSK) activate ade- 
nylate cyclase, which results in increases in cyclic 
adenosine monophosphate (cAMP) and activation of 
cAMP-dependent protein ldnase (PICA; Fig. 1).2 Less 
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is known about how activation of PICA or PKG leads 
to vasorelaxation. 
PICA and PKG are serine-threonine protein ki- 
nases that effect cellular processes through the phos- 
phorylation of specific substrate proteins. Three in 
vitro substrates for PKG, M r 240,000, 130,000, and 
85,000, were originally identified using homoge- 
nates of vascular tissue. 3 The 240 kDa substrate is 
likely the inositol 1,4,5-triphosphate (IPs) recep- 
tor. 4,5 Activation of PKG with phosphorylation of
the IP 3 receptor may lead to inhibition of IPs-in- 
duced Ca 2+ release. In addition to inhibiting Ca 2+ 
release, PKG may stimulate removal of intracellular 
Ca 2+. The 130 kDa substrate may represent he 
plasma membrane Cae+-pump. 6,7 Phosphorylation 
of the Ca 2+ pump increases its affinity for Ca 2+ . PKG 
may also reduce intracellular Ca 2+ via sequestration 
of Ca 2÷ by the sarcoplasmic reticulum through the 
phosphorylation of phospholamban (M r 6,000).  8,9 
Phosphorylation of phospholamban decreases its in- 
teraction with the Ca2+-ATPase, thus activating the 
Ca2+-ATPase. Thus one proposed mechanism of cy- 
clic nucleotide-dependent vasorelaxation is via de- 
creases in intracellular Ca 2÷ concentrations. 
The phosphorylation of myosin light chains 
(MLC20) and the thin filament regulatory proteins 
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Fig. 1. Two pathways have been implicated n mo ulating vascular smooth muscle relaxation. 
Adenylate cyclase (AC) activation by agents such asprostacyclin (PC), isoproterenol (ISO), and 
FSK, leads to increases in cAMP. cAMP activates cAMP-dependent kinase (PI(A). In addition, 
NO and NO donors, such as nitroglycerine (NTG) and SNP, activate guanylate cyclase (GC), 
leading to increases in cGMP. cGMP activates PKG. Protein ldnases such as PKA and PKG 
modulate cellular physiologic mechanisms through the phosphorylation of specific phospho- 
proteins (SP). A number of substrate proteins have been suggested to mediate vasorelaxation 
including the IP 3 receptor, the plasma membrane Ca2+-pump, hospholamban, and two 
unidentified 20 kDa proteins. The subsequent events that lead to dissociation of actin and 
myosin and relaxation have not been clearly determined. 
caldesmon and calponin have been implicated in reg- 
ulating vascular smooth muscle contraction. I°-12 
Thus the dephosphorylation f these proteins by 
protein phosphatases has been proposed as an addi- 
tional regulatory pathway for relaxation of smooth 
muscle. However, vasorelaxation can occur even 
when the extent of MLC20 and caldesmon phos- 
phorylation remain high. 11,13,14 Thus although acti- 
vation of protein phosphatases may be involved in 
vasorelaxation, the specific substrates that are de- 
phosphorylated have yet to be determined. 
Because the consequences of impaired vascular 
smooth muscle relaxation would be hypercontractil- 
ity, vasospasm, and impaired 0 2 delivery to tissues, it 
is likely that redundant systems are present in the 
vascular smooth muscles to modulate vasorelaxation. 
The purpose of this investigation was to examine late 
phase-signaling mechanisms uch as changes in 
[ Ca2+ ]i and phosphatase activation during cyclic nu- 
cleotide-dependent vasorelaxation. 
METHODS 
Materials. FSK, phorbol dibutyrate (PDBu), 
1,2-Bis(2-aminophenoxy)ethane-N,N,N',N'-tetra- 
acetic acid (acetoxymethyl ester) (BAPTA/AM), and 
isobutylmethylxanthine (IBMX) were purchased 
from Calbiochem (La Jolla, Calif.), SNP from 
Sigma Chemical (St. Louis), PKI and KEMPtide 
from Peninsula Laboratories (Belmont, Calif.), 
[32P]orthophosphate from Aanersham Corporation 
(Arlington Heights, Ill.), and calyculin from LC Lab- 
oratories (Woburn, Mass.). All other chemicals were 
of analytical grade. Protein weighting was performed 
using the DC Protein Assay (BioRad Corp., Her- 
cules, Calif.) 
Measurement of contractile responses. Bovine 
calf carotid arteries were obtained from a local abat- 
toir, dissected free of adventitial tissue, and opened 
longitudinally; the endothelium was then denuded 
with gentle rubbing of the intimal surface. Complete 
endothelial denudation using this technique has 
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Fig. 2. Representative tracing of BCASM relaxation responses. BCASM were equilibrated in
muscle bath and maximal contractile response to KC1 (110 mmol/L) was determined. Some 
strips were then subjected to Ca2+-free conditions and did not contract to a subsequent KCI 
(110 mm01/L) treatment. PDBu (300 nmol/L) treatment led to a slowly developing sustained 
contraction that nearly completely relaxed in the presence or absence of Ca 2 + with the addition 
of SNP (10 I.mol/L) or FSK (10 p~mol/L). 
been previously confirmed. 15 Transverse strips mea- 
suring 1 mm in diameter were cut, and a loop of 
surgical suture was tied to each end of the strip. The 
strips were mounted in a tissue bath system, and 
force was detected with Grass Transducers interfaced 
with a Gould Recorder. The strips were equilibrated 
in Krebs bicarbonate solution (KRB: 120 mmol /L  
NaCI, 4.7 mmol /L  KC1, 1.0 mmol /L  MgSO4, 1.0 
mmol /L  NaH2PO4, 10 mmol /L  glucose, 1.5 
mmol /L  CaCI2, and 25 mmol /L  Na2HCO3) at 
37 ° C and gassed with 95% 02, 5% CO2 for 1 hour. 
This provides an oxygen tension of 100 mm Hg as 
measured with a blood gas analyzer. The maximal 
contractile response for each strip was determined 
with high extracellular KC1 (110 mmol /L  with 
equimolar replacement of NaCI). The length of each 
strip was adjusted to give a maximal KCI contractile 
response. 'Because the muscles are hand-cut and 
-tied, the amount of contractile force that each mus- 
cle can generate varied. Thus all contractions were 
expressed as a percentage of this maximal KCI con- 
traction. 
For Caa+-free conditions the muscles were equil- 
ibrated in buffer without Ca 2+ containing 4 mmol /L  
EGTA (an extracellular Ca 2+ chelator) and 0.1 
mmol /L  BAPTA/AM (an intracellular Ca 2+ chela- 
tor) for 1 hour. 16 Depletion ofextracellular Ca 2+ was 
confirmed by a lack of contractile response to high 
KC1 (KC1 induces smooth muscle contraction by 
depolarizing the membrane resulting in an influx of 
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Fig. 3. There were no significant differences in the extent 
of relaxation i strips under Ca2+-containing (+)or Ca 2+- 
fi'ee ( - ) conditions treated with FSK ( 10 ~mol/L) or SNP 
(10 ixmol/L) in the presence or absence of IBMX (1 
retool/L) (n = 4 to 6 separate animals, 2 to 3 strips per 
animal). 
Ca 2+, thus KCI contractions are entirely Ca 2+- 
dependent). Depletion of intracellular Ca 2+ was de- 
termined by a lack of a contractile response to the 
agonist serotonin (serotonin activates a receptor 
leading to phosphoinositol hydrolysis and ultimately 
release of intracellular Ca 2 +). 
Intracellular Ca 2+ determinations. Intracel- 
lular [Ca2+]i was determined using aequorin as a 
Ca 2 + -indicator. ~7 Strips of bovine carotid artery were 
loaded with aequorin using a method that uses per- 
meablizing solutions. The strips were placed sequen- 
tially into four solutions for 30 minutes each: solu- 
tion 1:10 mmol/L EGTA, 5 mmol/L Na2ATP , 120 
mmol/L KC1, 2 mmol/L MgC12, 20 mmol/L TES; 
solution 2: 0.1 mmol/L EGTA, 5 mmol/L 
Na2ATP, 120 mmol/L KC1, 2 mmol/L C12, 20 
mmol/L TES, aequorin 0.2 mg/ml; solution 3:0.1 
mmol/L EGTA, 5 mmol/L Na2ATP, 120 mmol/L 
KC1, 2 mmol/L MgC12, 20 mmol/L TES; solution 
4: 5 mmol/L ATP, 120 mmol/L NaC1, 3.5 
mmol/L KC1, 1.5 mmol/L dextrose, 15.5 mmol/L 
NaHCO3, 10 mmol/L MgC12, 1.4 mmol/L 
NaH2PO 4. Aequorin signals and isometric tensions 
were measured simultaneously as test substances 
were added to the reservoir by perifusion. Light 
output was detected with a photomultiplier tube 
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Fig. 4. BCASM strips precontracted with the agonist se- 
rotonin (5-HT, 10 ixmol/L) or by depolarization with 
KCL (110 mmol/L) nearly completely relax with the ad- 
dition of FSK (10 Ixmol/L) or SNP (10 Fmol/L). How- 
ever, strips pre-contracted with the phosphatase inhibitor 
calyculin (CALYC, 100 nmol/L) are refractory to relax- 
ation with the addition of FSK (10 b~mol/L) or SNP (10 
txmol/L) (n = 4 to6 separate animals, 2 to 3 strips per 
animal). 
Measurement of PICA activity. PKA activity 
was determined with a phosphotransferase m thod 
an d a specific substrate peptide, KEMPtide, as previ- 
ously described) s The sensitivity of this method is 
not adequate to detect endogenous PKG activity. ]8 
Strips of bovine carotid artery smooth muscle 
(BCASM) were equilibrated for 1 hour in KRB, then 
exposed to PDBu (100nM) for 1 hour, followed by 
FSK for 15 minutes under Ca2+-containing and 
Ca2+-free conditions. The muscle strips were then 
homogenized (0.5 gm tissue/1 ml buffer) in 10 
mmol/L KPO4 (pH 6.8), 10 mmol/L EDTA, 10 
mmol/L 2-mercaptoethanol, and 1 mmol/L IBMX, 
using a Tissuemizer (Tekmar, Cincinnati). Homoge- 
nates were centrifuged at10,000g for 15 minutes at 
4 ° C and the supernatants were assayed. The assay 
was performed by combining 20 ~1 of supernatant 
with 40 ~tl of reaction buffer containing 40 mmol/L 
Tris (pH, 7.4), 20 mmol/L magnesium acetate, 100 
b~mol/L IBMX, and 500 tzmol/L Kemptide --- 10 
>mol/L cAMP. The reaction was started by adding 
10 >1 of 200 b~mol/L [a2p]-ATP (with a specific 
activity of approximately 200 cpm/pmol ATP) and 
terminated by spotting 20 b~l aliquots onto phospho- 
cellulose papers (Whatman P81). The papers were 
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Fig. 5. Intracellular Ca 2+ concentrations do not change in BCASM strips loaded with the 
photoprobe aequorin when stimulated with phorbol ester (DPB, 1 ~mol/L) or FSK (50 
~rnol/L). 
166 nM 
washed in cold 75 mmol/L phosphoric acid three 
times, rinsed in acetone, allowed to air dry, and were 
then counted in a scintillation counter (Beckman, 
Irvine, Calif.). 
Whole cell phosphorylation. Phosphorylation 
patterns of BCASM proteins were established from 
two-dimensional gel electrophoresis and autoradiog- 
raphy by a modification of Takuwa et al.19 Briefly, 
strips of BCASM were incubated in low-phosphate 
KRB containing 250 ~tCi/ml [32p]-orthophosphate 
to label intracellular ATP pools. The strips were un- 
stimulated (control), stimulated with PdBu (100 nM 
for i hour), stimulated with PDBu (100 nmol/L for 
1 hour) and then FSK (10 ~mol/L for 15 minutes) 
or SNP (10 ~mol/L for 15 minutes) in Ca =+ con- 
taining or Ca 2+ free conditions. Parallel contractile 
experiments were performed to confirm muscle via- 
bility. The tissues were immersed in dry ice-acetone 
and then crushed under liquid N 2. The samples were 
placed in homogenization buffer containing 20 
mmol/L Hepes pH 7.4, 20 mmol/L sucrose, 100 
mmol/L NaF, 15 mmol/L EDTA, 2 mmol/L 
EGTA, 1.3% SDS, and 10 mmol/L PMSF, and 
heated at 98 ° C for 5 minutes. The samples were 
centrifuged (10,000g for 10 min.), and the resulting 
supernatants were acetone precipitated. The proteins 
were resolubilized in 9 mol/L Urea and 2% CHAPS. 
100 &g of protein were adjusted to contain 9 mol/L 
Urea, 2% CHAPS, 100 mmol/L DTT, 15% Glyc- 
erol, and 2% Ampholines (1 part 4-6, 1 part 5-7, 
LKB Pharmaeia, Uppsala, Sweden). The proteins 
were resolved by IEF on slab gels. The lanes were cut 
out and scparated in the second dimension using 
Tris-Tricine gels (4% stack, 12% separating). 2° The 
gels were stained with Coomassie blue, dried, and 
exposed to Kodak XAR film. 
Statistical analysis. ~ Statistical analysis was per- 
formed by one-way analysis of variance using Sigma- 
star software (]andel Corp., San Jose, Calif.). Values 
are expressed as mean + standard error f the mean 
and p < 0.05 was considered significant. 
RESULTS 
Relaxation responses of BCASM. Strips of 
BCASM that were equilibrated under Ca2+-free con- 
ditions and precontracted with PDBu (300 nmol/L) 
relaxed with the addition of FSK (10 b~mol/L) or 
SNP(10 ~mol/L) (Fig. 2). There was no difference 
in the extent of relaxation under Ca2+-free condi- 
tions when compared with Ca2+-containing condi- 
tions when the muscles were relaxed with FSK (10 
b~mol/L) or SNP (10 ~tmol/L) with or without he 
addition of the phosphodiesterase inhibitor IBMX (1 
mmol/L, Fig. 3). 
Calyculin is a potent and specific phosphatase 
inhibitor that induces vascular smooth muscle con- 
traction. 21 BCASM that has been precontracted with 
KC1 (110 mmol/L) or serotonin (5-HT, 1 ~mol/L) 
completely relaxes with the addition of FSK (10 
Ixmol/L) or SNP (I0 b~mol/L) (Fig. 4). However, 
strips of BCASM that had been precontracted with 
calyculin were refractory to relaxation with the addi- 
tion of FSK (10 p~mol/L) or SNP (10 ~mol/L) (Fig. 
4). The muscles that had been precontracted with 
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Fig. 6. BCASM were treated with FSK (10 ~mol/L) and 
IBMX (1 mmol/L) for 15 minutes at 37 ° C. Control 
tissues remained in buff~er at 37 ° C. PKA activity ratios 
were determined as previously described. 13 Basal PKA ac- 
tivity was (0.46 _+ 0.04). Stimulation with FSK/IBMX 
resulted in PKA activation (activity ratio of  1) in Ca2+-free 
( -Ca 2+) or Ca2+-containing (+Ca 2+) conditions, and in 
the presence of calyculin (CALYC) (n = 4 separate exper- 
iments). 
calyculin were refractory to FSK (10 t~mol/L) and 
SNP (10 Ixmol/L) even in the presence of the potent 
phosphodiesterase inhibitor IBMX (1 mmol /L ,  data 
not shown). 
Intracellular Ca 2+ concentrations under 
Ca2+-free conditions. To determine that [Ca2+]i 
remained low and fixed under Ca2+-free conditions, 
[Ca2+]i was measured with the photoprobe ae- 
quorin. [Ca2+]i did not change with the addition of 
PDBu (100 nmol /L)  or with the subsequent addi- 
tion of  FSK (10 txmol/L) under Ca2+-free condi- 
tions (Fig. 5). 
Activation o f  PKA. To determine that calyculin 
was not impairing vascular smooth muscle relaxation 
via inhibition of PKA, endogenous PKA activity was 
determined with a phosphotransferase assay. The 
phosphotransferase assay for PKG activation is not 
sensitive nough to detect endogenous PKG activa- 
tion. 18 PKA activity is expressed as a ratio of the 
activity in the absence of cAMP to the activity when 
cAMP (10/xmol/L)  is added directly to the reaction 
mixture to stimulate maximal PKA activity. When 
PKA is activated endogenously, the catalytic unit is 
dissociated from the regulatory unit and results in 
maximal activity of the kinase. Thus an activity ratio 
A 
5 6 5 6 pl 
+Ca -Ca 
Fig. 7. Strips of BCASM were preincubated with 32p_ 
orthophosphate nd then no agonist (Control) (A); PDBu 
(100 nmol/L, 1 hour) (B); PDBu (100 nmol/L, 1 hour) 
followed by FSK (10 ~tmol/L, 15 minutes) (C); or PDBu 
(100 nmol/L, 1 hour) followed by SNP (10 Ixmol/L, for 
15 minutes) (D) Ca2+-containing (+Ca) or Ca2+-free 
conditions (-Ca). Phosphoproteins were resolved by iso- 
electric focusing followed by sodium dodecyl sulfate-poly- 
acrylamide gel electrophoresis. FSK and SNP resulted in an 
increase in phospholTlation f two 20 kDa phosphopro- 
reins with a pI of approximately 6 (arrows). The 20 kDa 
myosin light chain (m) is labeled for reference. This blot is 
representative of three separate experiments. 
of 1 correlates with total activation of PKA. Basal 
PKA activity was 0.46 + 0.04. PKA activity increased 
in BCASM stimulated with FSK (10 txmol/L) and 
IBMX (1 mmol /L)  under control (+Ca 2+, 0.93 + 
0.02), Ca2+-free ( -Ca  2+, 0.99 _+ 0.02) conditions, 
and in the presence of calyculin (100 nmol /L ,  
1.03 --- 0.03) (Fig. 6). This suggests that calyculin 
does not impair vascular smooth muscle relaxation 
via inhibiting PKA activation but rather that calycu- 
lin is modulating events downstream from PKA acti- 
vation. 
Phosphorylat ion of the 20kDa PICA substrate 
in BCASM with and without  Ca 2+. Two 20 kDa 
phosphoproteins have been shown to be endogenous 
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substrates for PICA and PKG activation. 19 Stimula- 
tion of BCASM with FSK (10 Ixmol/L) or SNP (10 
txmol/L) led to an increase in the phosphorylation f 
the two 20 kDa substrate proteins under Caa+-con - 
taining and Ca2+-free conditions (Fig. 7). Western 
blotting of two-dimensional gels with antibodies to 
known smooth muscle proteins of 20 kDa molecular 
mass (e.g. the small GTP binding protein RAP-1 or 
phospholamban) did not reveal cross-reactivity with 
these two substrate proteins (data not shown). Thus 
it is likely that these 20 kDa substrate proteins are 
novel phosphoproteins. Calyculin stimulation re- 
sulted in global nonspecific increases in phosphoryla- 
tion (data not shown). 
DISCUSSION 
Although increases in cyclic nucleotide concen- 
trations and activation of PKG and PKA have been 
implicated in vascular smooth muscle relaxation, the 
specific late phase-signaling events that modulate the 
vasorelaxation remain uncertain. One possible mech- 
anism of cyclic nucleotide-induced vasorelaxation is 
the reduction of intracellular Ca 2+ concentra- 
tions, s-~° However, vasorelaxation can occur in 
BCASM when the apparent intracellular Ca 2+ con- 
centrations are low and fixed (Fig. 2). In addition, 
increases in cAMP can induce Ca2+-independent re- 
laxation of uterine smooth muscleY These data sug- 
gest that alternate mechanisms that do not rely on 
changes in intracellular Ca 2+ may also mediate vascu- 
lar smooth muscle relaxation. 
Vascular smooth muscle relaxation may be regu- 
lated by a balance between protein ldnase and pro- 
tein phosphatase activity. Phosphatases have been 
implicated in regulating smooth muscle contractile 
states. The addition of phosphatase inhibitors to 
smooth muscles leads to contraction. 2~ Contractions 
induced by the phosphatase inhibitor calyculin are 
refractory to relaxation with FSK or SNP (Fig. 4). 
Treatment with calyculin does not inhibit PICA acti- 
vation (Fig. 6), thus it is likely that calyculin is acting 
on events downstream toPICA activation. These data 
suggest that phosphatase activation may regulate vas- 
cular smooth muscle relaxation. However, the spe- 
cific dephosphorylation events that correlate with 
cyclic nucleotide-dependent vasorelaxation have not 
been clearly determined. 
Cyclic nucleotide-dependent vasorelaxation is as- 
sociated with an increase in the phosphorylation f
two low molecular weight 20 kDa substrate pro- 
reins) 8,19 In addition, these two 20 kDa substrate 
proteins are not phosphorylated in a vascular smooth 
muscle that is uniquely refractory to cyclic nucleo- 
tide-dependent vasorelaxation, human umbilical ar- 
tery smooth muscle.~8 An increase in the phosphory- 
lation of these proteins is associated with cyclic 
nucleotide-dependent vasorelaxation when the intra- 
cellular Ca2+-concentrations are low and fixed (Fig. 
7). Thus these data indicate hat there is a distinct 
correlation between the phosphorylation of these 
two 20 kDa phosphoproteins and cyclic nucleotide- 
dependent vasorelaxation. Further work is needed to 
determine whether these proteins are specific PICA 
and/or PKG substrates and to identify and charac- 
terize these proteins. 
Taken together, these data and the data pre- 
sented by other investigators suggest hat there are 
three possible cellular signaling mechanisms that are 
involved in cyclic nucleotide-dependent vasorelax- 
ation: (1) decreases in intracellular Ca2+; (2) the 
activation of protein phosphatases; and (3) the phos- 
phorylation of two unidentified 20 kDa phosphopro- 
teins. It is possible that multiple late phase-signaling 
mechanisms are present to mediate cyclic nucleotide- 
dependent vascular smooth muscle relaxation. 
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